Hosted on MSN2mon
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).
MyChesCo on MSN4mon
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...
pharmaphorum8d
Alarm bell rings for GSK as US policy dents RSV jab sales
Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
pharmaphorum5d
GSK to lean on Zhifei for Shingrix and maybe Arexvy in China
The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...
Fortune1y
Emma Walmsley
Early in 2023, British pharma giant GSK launched the world’s first RSV adult vaccine, Arexvy, for those aged 60 years and older. Walmsley, the only woman CEO of a major pharma company ...
SBS1y
Australia approved it's first RSV Vaccine. Will you be eligible for this now?
The Therapeutic Goods Administration (TGA) has approved AREXVY to be used as a RSV vaccine for Australians aged 60 and over.